Introduction
Reactive oxygen species (ROS) are atoms or molecules with one or more uncoupled electrons. ROS that occur during physiological and pathological processes may damage cell compounds such as lipid, protein, carbohydrate and DNA. 1, 2 Oxidative stress appears when the production of ROS exceeds the removal capacity. The ROS reactivity towards various molecular targets leads to oxidative damage contributing to different human pathologies. Despite the presence of the cell's antioxidant defense system to counteract oxidative damage from ROS, radical-related damage may play a key role in the development of age-dependent diseases such as cancer, arteriosclerosis, arthritis, neurodegenerative disorders and other conditions. 3 Some studies reported that free radicals may play role in epilepsy. 4, 5 Generalized epilepsy may increase the content of ROS and superoxide generation in the brain. 6, 7 Seizureinduced lipid peroxidation has been reported by measuring products such as thiobarbituric acid reactive substances 8 and F2-isoprostanes (F2-IsoPs) in rat brain tissue. 9 In vivo detection of free radicals is difficult because of their very short lifetimes; other parameters are used to measure oxidative stress. Considering that lipid peroxidation is one of the most biological important free radicals reactions, 10 changes in lipid oxidation markers are commonly used as indicators of oxidative stress in clinical laboratory settings. 11 Lipid peroxidation often appears in response to oxidative stress, and a great variety of aldehydes are formed when lipid hydroperoxides break down in biological systems. The methods used detection of conjugated dienes, lipoperoxides, and aldehydes are poorly reproducible and unreliable when carried out in plasma because of the extreme reactivity and instability of the species. 12 Some researchers reported the production of a series of prostaglandin F2-like compounds (F2-isoprostanes, F2-IsoPs), which are formed in vitro and in vivo by free radical-catalyzed peroxidation of phospholipid-bound arachidonic acid, a pathway which is independent of the cyclooxygenase pathway.
Purpose: We aimed to investigate the effects of levetiracetam on oxidative stress which is one of the new antiepileptic drugs in epileptic patients. Methods: The study consisted of 21 patients with cryptogenic partial epilepsy. We determined the urinary 15F-2t-isoprostane levels of the 30 patients which is a marker of oxidative stress. Morning urine samples were collected from the patients before beginning LEV and after 3 months treatment. Of these patients 9 were excluded from the study that had seizure history in the last 1 month. Urinary levels of 15-F2t-isoprostane determined by ELISA initially and after 3 months treatment for each patient.
Results: Mean age of the 21 patients was 29.6, of these 11 were females and 10 males. Mean urinary 15F-2t-isoprostane level of the patients was 876 AE 447 ng/mg Cr before the treatment of LEV. After 3 months treatment the mean 15F-2t-isoprostane level of the patients was 1560 AE 630. The patients had significantly higher levels of urinary 15F-2t-isoprostane when compared with initial levels (p = 0.025).
Conclusion:
Our results showed the increase of urinary 15F-2t-isoprostane levels in epileptic patients whom were treated with LEV which may indicate that LEV induces the oxidative stress in epileptic patients. ß 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
excreted in urine. 15 F2-IsoPs may be considered as the most reliable markers of oxidative stress 16 and can be used to evaluate the oxidative stress in several of human pathologies. At the same time, this is also the conclusion of a multilaboratory validation study of the National Institute of Environmental Health Sciences. 17 In some studies it was shown that valproic acid treatment in epileptic children increased the urinary levels of 15-F2t-IsoP which is a marker of oxidative stres. 18 But there is not any study about the effect of levetiracetam on levels of the urinary15-F2t-IsoP. The aim of our study was to evaluate levels of urinary isoprostane levels of epileptic patients, and then to determine whether the treatment of levetiracetam might influence the urinary isoprostane levels before and 3 months after therapy.
Materials and methods
All research procedures were approved by the University of Dumlupinar Institutional Review Board and Eskisehir Osmangazi University, Medical Faculty. Initially, the study consisted of 30 patients with cryptogenic partial epilepsy. Of these patients 9 were excluded from the study that had seizure history in the last 1 month. All patients were subjected to detailed clinical examination for evaluation of neurological status. Electroencephalography (EEG) was conducted on all patients. MRI scan was done for more detailed examination. All patients were suffering from cryptogenic partial epilepsy. The patients who received levetiracetam (1000-3000 mg/day) for 3 months and who did not have any clinical epileptic seizure during for the last 1 month were included. Our exclusion criteria were abnormal neurological examination, abnormal cerebral MRI scan, endocrinopathies, liver, heart, kidney diseases, cancer, and any disease likely to affect lipid metabolism, any inflammatory disease, and a body mass index (BMI) > 25. Patients with past or concurrent diseases which might affect the activity of antioxidant enzymes were excluded from the study. Mean age of the 21 patients whom lasted the study were 29.6, of these 11 were females and 10 males. Blood samples were taken first day of therapy. Urine samples were collected from the participants beginning LEV and after 3 months treatment. Blood samples were collected in serum separator tubes, allowed to clot for 30 min, centrifuged at room temperature for 15 min at 2000 Â g. The biochemical measurements were done immediately, by using commercial available kits. The urine samples were stored at À80 8C until analyzed. Routine blood count and chemistry analysis and urinalysis were performed for each patient, and those with abnormal results were excluded. Urinary levels of 15-F2t-isoprostane determined by ELISA first and last day for each patient.
Urinary 15-F2t-IsoP immunoassay
Urinary 15-F2t-IsoP levels were analyzed using immunoassay kits from Oxford Biomedical Research (Product number; EA 85). Urine samples without additives added were thawed to room temperature and diluted 1:2 using the dilution buffer provided with the kit. Analysis was done according to the recommendations of the manufacturer according to Fig. 1 . Urinary levels are dependent on the hydration status of the subject. To normalize 15-F2t-IsoP levels, urinary creatinine was assayed using a creatinine kit from Oxford Biomedical Research (Product number; CR 01) in Fig. 2 . 15-F2t-IsoP concentration was expressed as nmol 15-F2t-IsoP/mmol creatinine.
Statistical analysis
All statistical analysis was performed with the computer program ''SPSS for Windows'' (SPSS Inc; Release 11.5; September 6, 2002). All of the data were expressed as means AE SD. Differences between groups were evaluated by one-way analysis of variance (ANOVA) followed by Tukey's multiple comparison tests. The significance was tested at n.s. p > 0.05, p < 0.05, p < 0.01 and p < 0.001. 
Results
Initially, mean urinary 15F-2t-isoprostane levels of the patients were 876 AE 447 ng/mg Cr. After 3 months treatment of LEV, the mean 15F-2t-isoprostane levels of the patients were 1560 AE 630. The patients had significantly higher levels of urinary 15F-2t-isoprostane when compared with initial levels (p = 0.025) in Fig. 3. 
Discussion
In this study, the oxidative status in epileptic patients before and 3 months after levetiracetam therapy was evaluated. The seizures mediated brain injury is a dynamic process that includes multiple factors such as genetic factors, the extent of glutamate-mediated excitoxicity leading to disturbances in intracellular electrolyte metabolism, mitochondrial dysfunction, oxidative stress and changes in cytokines. 19 Some studies reported an increase in oxidative status in the brain of animals probably caused by recurrent seizures. 6, 7 Free radical generation may induce seizure activity by inactivation of glutamine synthase. Thus, oxidative stress could exacerbate the etiology of epilepsy. 6 There are some conflict results in oxidative stress in epilepsy. Some authors reported that increased lipid peroxidation of brain tissue was in ferric chloride and kainate-induced epilepsy in experimental studies. 8, 20 Patel et al. demonstrated that seizures induced the increase in isofurans (novel products of lipid peroxidation) formation and its correlation with changes in hippocampal pO 2 and mitochondrial dysfunction. 21 The conflicting results in oxidative stress in epilepsy have not been exactly explained in the literature. The variation of reported results may result from patients included the study different forms of medication, type of seizure, obesity. F2-Isops are desirable index of lipid peroxidation in vivo because they are specific products of lipid peroxidation, detectable in normal biological fluids, modulated by antioxidant status; and unaffected by dietary lipids and they increase dramatically in models of oxidant injury. 22 F2-IsoPs are not only most reliable markers of oxidative stress 16 but also have some biological effects such as vasoconstriction with ischemia of the retina which account for retinopathy of prematurity. 23 Patel et al., showed that status epilepticus results in the formation of lipid peroxidation end products. Status epilepticus transiently decreases hippocampal oxygen tension and F2-IsoP occurs during these hypoxic phase whereas the formation of isofurans occurs when the tissue oxygen levels return to normal. These data suggest that seizure-induced changes in tissue oxygen levels and mitochondrial dysfunction may differentially influence the formation of F2-IsoPs and IsoFs. 21 Free radicals and ROS may play role in epilepsy. 4, 5, 24 Long-term use of anticonvulsants has been shown to increase free radicals formation and cause oxidative damage within neuronal cells. 25 There are several studies about the effect of valproic acid treatment on 15-F2t-isoprostane levels. 26, 27, 18 Tong et al. reported that the plasma and liver levels of 15-F2t-isoprostane was increased in rats after their treatment with VPA. 26 Moreover, they reported VPA-induced formation of 15-F2t-IsoP is associated with VPA glucronidation. 27 Michoulas et al., demonstrate that treatment of children with VPA is associated with higher urinary levels of 15-F2t-IsoP, a marker of oxidative stress. 18 But there is no knowledge about effect of levetiracetam treatment on urinary 15-F2t-isoprostane levels. The report of the subcommittees of American Academy of Neurology and American Epilepsy Society suggested that levetiracetam have no serious adverse events and no known interactions with oral contraceptives, warfarin, enzyme inducer and other antiepileptic drugs. 28 Our results showed the significant higher levels of urinary 15F-2t-isoprostane levels in epileptic patients under LEV treatment when compared with the initial levels. Considering the present findings, it can be suggested that patients on LEV therapy may be at risk of developing oxidative stress as shown by the remarkably high urinary 15-F2t-isoprostane levels.
